Vitafoods Show Floor Preview: Exhibitors A–G

Why It Matters

These launches signal rapid expansion of ingredient portfolios aimed at weight‑loss, healthy‑aging and GLP‑1‑related markets, reshaping product pipelines for food and supplement manufacturers. The breadth of innovations highlights escalating consumer demand for scientifically backed, convenient functional solutions.

Key Takeaways

• 3H Labs' steamed ginger extract reduces body fat and cholesterol
• AB‑Biotics offers probiotic blends for joint, immune, cardiovascular, skin, menopause
• Arla's high‑protein dairy concepts target GLP‑1 anti‑obesity medication users
• Balchem introduces choline‑enriched folate and probiotic excipient platforms
• DolCas launches melt‑in‑mouth collagen sachets for on‑the‑go absorption

Pulse Analysis

The 2024 Vitafoods show is turning into a showcase for next‑generation functional ingredients, reflecting a market that is increasingly health‑centric and data‑driven. With obesity rates climbing and GLP‑1 anti‑obesity drugs gaining traction, companies such as Arla Foods Ingredients and 3H Labs are delivering high‑protein dairy formats and clinically validated ginger extracts that promise weight‑loss and cholesterol benefits. Simultaneously, the aging demographic fuels demand for probiotic and postbiotic solutions, prompting AB‑Biotics, Balchem and Fytexia to roll out targeted strains and peptide regulators that address joint health, immune function, and metabolic resilience.

Beyond core nutrients, the exhibition highlights a surge in delivery‑technology innovation. Concordix’s patented emulsion system enables stable, chewable matrices that protect sensitive actives, while DolCas Biotech’s melt‑in‑your‑mouth collagen sachets offer a convenient, water‑soluble format that bypasses traditional mixing requirements. Balchem’s new excipient portfolio, StabiliPro, and its choline‑enriched folate Optifolin+ illustrate how ingredient manufacturers are bundling functional efficacy with improved stability and bioavailability, catering to formulators seeking clean‑label, high‑performance solutions.

For manufacturers, these developments translate into expanded formulation options and faster time‑to‑market for premium products. The convergence of clinically backed claims, novel delivery platforms, and ingredients tailored to emerging therapeutic niches—such as GLP‑1 companion nutrition and menopause support—creates a competitive edge for brands that can integrate them effectively. As consumer expectations evolve toward personalized, science‑backed nutrition, the trends highlighted at Vitafoods are likely to shape product pipelines and supply‑chain strategies throughout 2025 and beyond.